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Abstract 
Objectives In pharmaceutical drug development, preclinical tests in animal models are 
essential to demonstrate whether the new drug is orally bioavailable and to gain a first insight 
into in vivo pharmacokinetic parameters that can subsequently be used to predict human values. 
Despite significant advances in the development of bio-predictive in vitro models and 
increasing ethical expectations for reducing the number of animals used for research purposes, 
there is still a need for appropriately selected pre-clinical in vivo testing to provide guidance on 
the decision to progress to testing in humans. The selection of the appropriate animal models is 
essential both to maximise the learning that can be obtained from such experiments and to avoid 
unnecessary testing in a range of species. 
Key findings The present review, provides an insight into the suitability of the pig model for 
predicting oral bioavailability in humans, by comparing the conditions in the GIT. It also 
contains a comparison between the bioavailability of compounds dosed to both humans and 
pigs, to provide an insight into the relative correlation and examples on why a lack of correlation 
may be observed.  
Summary While there is a general trend towards predicting human bioavailability from pig 
data, there is considerable variability in the data set, most likely reflecting species specific 
differences in individual drug metabolism. Nonetheless, the correlation between pigs vs 
humans was comparable to that reported for dogs vs. humans. The presented data demonstrate 
the suitability of the pig as a preclinical model to predict bioavailability in human. 
  
Keywords; mini-pigs, oral drug absorption, physiologically based pharmacokinetic (PBPK), 
pigs, preclinical animal model  
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1 Introduction 
In pharmaceutical drug product development, selection of the best lead drug candidate, defining 
how to formulate and to develop it into a newly licensed medicine is a complicated, costly, and 
risky process [1]. Over the last few decades, despite huge advances in therapeutic target 
discovery and the number of drug molecules entering development programs, the number of 
drug products (i.e. medicines) licensed for clinical use has decreased consistently [2]. Thus, there 
is a clear need to develop new technologies to improve the developability of emerging drug 
candidates and to unlock key bottlenecks stifling innovation in pharmaceutical development. 
New methods of reliably assessing the quality, safety and efficacy of emerging medicines are 
required to drive change in the drug product development process from the traditional ‘trial and 
error’ testing approach to selecting the most appropriate tests and avoiding costly development 
delays. Introducing more clinically relevant testing methods will make drug product 
development more cost-effective, reduce unnecessary testing, and ultimately facilitate earlier 
access to market for new medicines. This strategy towards more reliable pre-clinical testing has 
parallels with the recently proposed biopharmaceutics risk assessment roadmap (BioRAM) for 
optimising drug product development and clinical performance [3]. A key tenet of the BioRAM 
approach is to move from a “test and confirm” to a “learn and confirm” development paradigm, 
where predictions will be made in the ‘learn phase’ on how to maximise medical value for a 
new drug in advance of in vivo studies, and in vivo studies become ‘confirmatory’ rather than 
‘exploratory’ [3]. 
 
Operating within the conventional drug product development paradigm involves initially in 
vitro screening, pre-clinical testing followed by clinical evaluation in humans. There are two 
key stages where improvements in applying a ‘learn and confirm’ paradigm could be sought. 
Firstly, the link between the in vitro testing and the pre-clinical evaluation in vivo, there is a 
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need for an improved bio-relevance of screening conditions that truly reflect the pre-clinical 
animal model conditions, so the pre-clinical in vivo testing becomes confirmatory of in vitro 
tests. Secondly, there is a need to validate the reliability of pre-clinical models to predict 
performance in humans, so that clinical studies become truly confirmatory of pre-clinical 
investigations. 
 
When attempting to make a priori prediction whether a new drug product will be bioavailable 
in vivo, a thorough understanding of the factors influencing drug absorption is essential. 
However, the process of oral drug absorption is complex, which is influenced by numerous 
factors including (a) the physiochemical properties of the drug, (b) formulation related factors 
such as formulation type and excipients used, and (c) physiological, genetic, biochemical and 
pathophysiological factors in the gastrointestinal (GI) tract. While the utility of bio-relevant in 
vitro and in silico models for predicting absorption potential, based on physiochemical 
properties of the drug substance, are well established, there are gaps in our knowledge on the 
interplay of drug, gastrointestinal physiology and formulation excipients on in vivo drug 
absorption. These gaps limit the ability to reliably predict in vivo behaviour for formulated drug 
products. Therefore, pre-clinical in vivo assessment of prototype drug formulations is routinely 
required, involving potentially a range of pre-clinical animal species, such as rats, dogs, pigs 
and non-human primates.  
 
When considering the most suitable animal model to predict bioavailability or bio-performance 
in humans, a detailed understanding of physiological, anatomical and biochemical differences 
between different animal models is required [4]. In pre-clinical ADMET studies, commonly two 
animal species are used – one rodent and one non-rodent. There are limiting factors in the use 
of rodent species as an animal model to investigate the impact of drug formulation on 
bioavailability, such as the small liquid volume in the gastrointestinal tract [5], limited dose size 
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and the generally higher metabolic rate [6], where the latter may also provide an obstacle for 
reliably predictions of human pharmacokinetics. The most common rodent model is the rat. 
Rats are considered to be good predictors of intestinal permeability in humans and have been 
shown to display similar intestinal absorption profiles (i.e. correlation > 0.8 between 
permeability estimates in rat and humans for 16 compounds encompassing both passive and 
carrier mediated substrates) and similar transporter expression patterns in the small intestine [7]. 
However, there are major differences between the two species that limit the utility of rats for 
predicting bioavailability in humans, including distinct expression levels and patterns for 
metabolizing enzymes in the intestine, and anatomical differences such as size, gastrointestinal 
length, pH profile and transit time [7]. 
 
There have been extensive discussions in the literature on the use of dog and non-human 
primate models to predict oral bioavailability in humans and the merits of pre-clinical models 
have been well described recently [8; 9]. In principle, non-human primates are considered the 
closest model to humans, notwithstanding discrepancies with respect to intestinal metabolism 
which have been recently reviewed [8]. However, apart from ethical considerations for using 
non-human primates for routine pre-clinical testing, studies involving non-human primates 
are prohibitively expensive. Dogs have traditionally been the most commonly used large 
animal model in pharmaceutical drug product development. However, there are notable 
difference in the gastrointestinal tract relative to humans that must be considered [10]. The pH 
in the fasted state canine stomach is considered to be on average higher and more variable 
than in humans, ranging between 1.5 and 6.8. As a result, it is common to pre-dose dogs with 
pentagastrin, whereby gastric pH is lowered. 
 
In contrast, there is much less published information on the suitability of pigs for assessing 
bioavailability of oral drug products. The use of pigs in pre-clinical assessments has increased 
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in recent years [11; 12]. A principle advantage of the pig model is the similarity between 
gastrointestinal tract anatomy and physiology of humans and pigs [13; 14]. Pigs, like humans, 
are omnivorous [15], they have similar digestive system [4; 16; 15] and they are a suitable model 
for evaluation of most ADMET endpoints [16]. Moreover, the intestinal microbiome of the 
colon and the digestion characteristics of the small intestines are considered to be similar to 
man [17]. Analogies among pigs and human include skin structure, cardiovascular system, 
urinary system as well as the immune system [13]. There are several breeds of pigs used in 
pharmaceutical research, ranging from the domestic Landrace (LR) to more selectively bred 
miniature-sized pigs, such as Göttingen, Yucatan, Hanford, Sinclair minipigs. Göttingen 
minipigs are the most commonly used, and were originally developed by crossbreeding the 
Minnesota minipig, Vietnamese potbelly pig and German Landrace pig [18]. While there are 
gaps in the literature on the possible breed specific difference in gastrointestinal physiology, 
the mostly widely characterised are the LR and Göttingen minipig [19]. 
 
In summary, with the increasing emphasis on expediting drug product development (or a ‘quick 
win, fast fail’ paradigm), drug development scientists must operate in reduced time-lines to 
provide a drug formulation that provides efficient and reliable bioavailability in vivo. Selecting 
the most suitable pre-clinical animal model is essential to demonstrate the efficacy of the drug 
formulation in vivo and to provide early predictors of the likely performance in humans. While 
the merits and limitations of rat, dog and non-human primate models have been extensively 
reviewed in the literature, the purpose of this review is to focus on the pig and its suitability as 
a model in drug product development. Furthermore, an extensive review of the literature was 
completed to harness knowledge from previous studies involving bioavailability assessment of 
drugs in pigs with the objective of assessing the degree of correlation between human’s and 
pig’s bioavailability, which to the best of our knowledge have not been published elsewhere. A 
secondary goal of this work was to compare the pig model to the more commonly used dog 
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model, which will facilitate the more critically informed decisions on which pre-clinical species 
to select in drug product development.    
 
2 Comparing the gastrointestinal tract of pigs and humans 
To determine the suitability of the pig for pharmacokinetic studies, an understanding of the 
conditions in the GI tract is essential. Differences in the anatomical and physiological 
characteristics of the GI tract can impact formulation performance and drug absorption. The 
next section will directly compare the pig to human GI tract conditions with the focus on 
identifying key differences. 
 
2.1 Gastrointestinal pH 
The impact of the GI pH on oral drug absorption in humans is well established by affecting 
parameters such as solubility, ionization and stability [20]. In particular, the acidic pH of the 
stomach can have a significant influence on drug product performance, particularly for drugs 
displaying pH dependent solubility. The gastric pH during the fasted state in pigs and humans 
is broadly similar, for example the stomach pH in the fasted pig is 1.2 - 4.0 [21], compared to 
reported ranges for humans, of 1.0 - 3.5 [22]. A more detailed overview of the pH along the 
length of the GI tract is presented in Table 1 which demonstrates a similar increase in the pH 
pattern in the small intestine and a pH reduction in the colon compared with humans. 
Interestingly, the pH profiles between pigs and humans in both the fasted and fed states were 
comparable. This is one distinct advantage of the porcine model versus the canine model and 
particularly important in terms of suitability of the pig model for predicting the performance of 
drug dosage forms that are likely to be influenced by the pH. This is pertinent for modified 
release dosage forms, where a pH change can act as a trigger for drug release in the intestinal 
lumen, e.g. gastric resistant tablets or colonic delivery based upon a pH sensitive polymer.  
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2.2 Intestinal physiology 
While there are external morphological differences between humans and pigs, their internal 
physiology is considerably similar [4; 15; 26]. At maturity, the total length of the pig intestine is 
reported to be longer in pigs (24 cm/kg [26]) compared to the human intestine which is 
estimated to be 14 cm/kg. However, the reported values of total GI tract length vary widely in 
pigs, with values as much as 23 m in length, depending on the size and weight of the pig, as 
well as the type of measurement technique employed in various studies [4; 15; 26]. Furthermore, 
the anatomical arrangement of the large intestine is different between pigs and humans. In 
humans the large intestine can be described in ascending, transverse and descending colon 
forming a square like configuration, which ends in the s-shape of the sigmoid colon [15]. In 
pigs, the large intestine is described as a spiral colon, where the distinct sections of the colon 
are arranged in a series of coils [13; 15]. Despite these differences, the relative length of each of 
the three major intestinal segments (as a % of overall length) are similar between pigs and 
humans, as illustrated in Figure 1. Merchant et al., demonstrated that the length of each 
section in pigs with an average weight of 95-110kg is comparable to humans, comprising 
82 %, 17%, 1% vs. 65%, 33% & 2.5% for the small intestine, colon and caecum, respectively 
[4; 26]. Normally, smaller pigs are used in preclinical studies, therefore, it is interesting to note, 
that similar studies in smaller landrace pigs (average weight 18 kg) showed that the intestinal 
sections are also relatively similar. Differences in relative % lengths of the GI tract could 
potentially influence the type of formulation to be studied in a pig model. Merchant et. al 
reported that the amount of water in the pig intestine (18g/kg body weight) was higher than in 
human intestine (8.2g/kg body weight) [26]. A greater amount of water within the porcine 
intestinal tract may also merit consideration in terms of the dosage form disintegration and 
potential impact on drug dissolution.  
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Given that the surface area available for drug absorption is a critical factor for passive diffusion 
across the intestinal membrane, a comparison of the surface area of the pig versus human 
intestine is pertinent (Table 2). DeSesso and co-workers investigated the absorptive surface 
area in the lumen of the small intestine of pigs and compared this to human surface area. Using 
a basic cylindrical estimate of the luminal surface area, of the small intestine of a 70kg human 
versus a 47kg pig, the pig’s intestinal surface area appears to be higher than the human’s area, 
at 1.4m2 versus 0.42 m2 respectively. However, given that the apical ‘brush border’ on 
enterocytes of both humans and pigs is composed of pilicae, villi and micro-villi, a more 
accurate estimate of the total surface area that take these factors in account, suggested that the 
intestinal absorptive surface area of humans and pigs are comparable, at 252 m2 and 168-210 
m2  respectively [27].  
 
2.3 Bile composition 
Bile salts are amphiphilic molecules and intrahepatic bile acids undergo further conjugation 
with glycine and taurine [28]. Once synthesized and conjugated in the hepatocyte, bile acids are 
transported into the biliary tract, secreted through the hepatic duct into the gallbladder. During 
food intake the bile fluid is secreted into the duodenum, mediated by cholecystokinin and 
secretin [29]. In some animal species bile is secreted continuously (e.g. rats), whereas pigs have 
a secretion pattern similar to humans [4; 30]. Once secreted into the intestine, the central 
function of bile acids is the solubilisation of dietary lipids and promotion of their digestion 
and absorption. Thus, bile salts can have a significant influence on drug absorption, and in 
particular promote the solubilisation of poorly water soluble drugs [31]. 
 
Bile acids can be classified into primary and secondary bile acids; chenodeoxycholic acid and 
cholic acid are primary bile acids in many species, including pigs and humans [32]. Secondary 
bile acids are formed by bacterial hydrolysis of conjugated bile acids in the large intestine. The 
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major bile acids present in pigs and humans are summarized in Table 3 and a comparison of 
the bio-synthesis pathway for bile salts between the two species is presented in Figure 2. A key 
difference between bile composition between pigs and humans is hyocholic acid, which is the 
major primary bile acid in pigs. Hyocholic acid is synthesized in pigs by 6α-hydroxylation of 
chenodeoxycholate [32], whereas in humans only small amounts of hyocholic acid and 
hyodeoxycholic acid exists [33; 34]. In humans, CYP3A4 has been identified as the relevant 
enzyme for the 6α-hydroxylase reaction of hyocholic acid biosynthesis [35]. In pigs, the primary 
structure of the porcine 6α-hydroxylase enzyme showed 75% identity with members of the 
CYP4A subfamily in human [32].  
 
In both humans and pigs, the major bile components are conjugated with taurine or glycine [36], 
with the majority (~80%) being conjugated with glycine[37]. In pigs, the rank order of prevalence 
of bile salts in the intestine is glyco-hyoycholate (44.4%), glyco-chenodeoxycholate (31.2%), 
glycol-hyodeoxycholate (8.2%), tauro-hyocholate (6.8%) and tauro-chenodeoxycholate 
(6.6%), as illustrated in Figure 3 [38; 39]. By comparison, the most prevalent intestinal bile salts 
in humans are glyco-cholate (36.5%), glycol-chendeoxycholate (33%), glyco-deoxycholate 
(10%), tauro-cholate (6.8%) and tauro-chendeoxycholate (6.7%).  
 
Given the key role bile acids play in the drug absorption process it is still unclear what impact, 
if any, theses compositional differences in bile have on drug absorption. Also given that bile 
composition is highly influenced by fasted and fed states in humans, there is a need to improve 
knowledge on bile secretion profiles in the fasted and fed porcine intestine. 
 
2.4 Gastrointestinal transit time 
Formulations that enter the GI tract must pass through several sections, of which some are 
specialised for absorption and others for holding and digesting food. The stomach is used for 
Pig as a preclinical model of oral drug absorption 
Page 12 
 
holding food and therefore can delay transit through the small intestine. The small intestine is 
the main absorptive site of drugs and nutrients in both pigs and humans. A comparison of the 
different transit times through the sections is crucial to increase the understanding of the pig as 
a pre-clinical animal model. The small intestine transit time is the most important time for drug 
absorption during the GI tract, it is reported to be similar in pigs and humans, 3-4 h in pig 
compared to 2-4 h in humans [10; 6; 41]. As described in previous sections the physiology of the 
small intestine is also comparable, consequently, the drug absorption in the small intestine in 
pigs is thought to be similar to the absorption in humans. 
 
The gastric emptying time is an issue which has received much discussion when considering 
the suitability of pigs for assessing oral pharmacokinetics. The gastric emptying rate in pigs is 
considered to be longer and more variable than in humans. Human gastric transit is reported to 
be 10 – 15 minutes for liquids and can be up to 2 hours for indigestible solids [24]. By 
comparison, reported values of gastric emptying in pigs display wide variability.  This may 
reflect a physiological difference of the stomach of pigs, which has a muscular outpouching 
called the torus pyloricus that can cause food to be retained in the stomach for prolonged period 
of up to 24 hours [15]. Alternatively, methodological differences in how the gastric emptying 
rate is determined can lead to variable estimates. Hossain et al. [21] reported an extraordinary 
long and highly variable gastric emptying time of 1 – 28 days measured by the emptying of a 
solid dosage form from the stomach. A trend towards an increased gastric emptying time was 
observed with increasing density of the dosage form. However, this study was limited in that it 
involved only two pigs that were repeatedly dosed for a prolonged period. In another study 
Oberle and Das [25] reported a shorter gastric emptying time in pigs of 6-24 hours, albeit still 
highly variable and longer than comparable values in humans [21; 25]. In contrast. Davis et al. [6] 
reported that the gastric emptying time after a light meal ranged between 1.5 - 6 hours in 
landrace pigs, and therefore was closer to human estimates, based upon investigations of the 
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gastric emptying of liquids and solid dosage forms in pigs using gamma scintigraphy [6]. Davis 
et al. [6] also reported the mean time to empty 50% of a dosed liquid to be 1.4 hours in pigs, 
compared to reported estimates of 11 -14 minutes for a solution in man [42]. The gastric 
emptying rate of pellets in pigs (pellet size of 0.85 -1.4 mm), was 2.2. h for 50% of the pellets 
to enter the small intestine and 4 hours after dosing a non-disintegrating tablet [6]. The small 
intestinal transit time in the pigs was reported to be constant on 3-4 hours for the three dosage 
forms (solution, pellets and tablet), the total transit time was between 24 and 48 hours for three 
of the 4 pigs, one pig showed an unusually long total transit time of 72- 96hours [6].  
 
More recently, Christiansen et al. [43] investigated the possibility of using Göttingen mini-pigs 
to investigate fasted versus fed state differences in oral bioavailability, and as part of the study, 
co-administered paracetamol was used as a marker for gastric emptying. Christensen and co-
workers reported gastric emptying rates in the fasted animals to be 4-6 hours. After 
administration of FDA standard breakfast to mini-pigs (5 or 10 g/kg) or a nutritional drink (10 
or 20 g/kg) the gastric emptying rate did not increase, but rather tended to decrease slightly. A 
possible explanation for this apparent lack of impact of food on gastric emptying may indicate 
that fasted pigs retain food in the stomach for prolonged periods, and hence are not dosed in a 
‘truly’ fasted state. This hypothesis was further explored by Suenderhauf et al. [44] where pigs 
were pre-dosed with the pro-kinetic drug metoclopramide, followed by a post mortem 
determination of the stomach contents weight. In metoclopramide pre-treated pigs, the weight 
of the stomach contents was lower compared to the non-treated groups, suggesting that this is 
a potential approach to mimic a fasted state condition. In contrast, however, a recent study by 
Henze et al. [45] did not observe an effect of pre-treating with metoclopramide on the gastric 
emptying rate in minipigs, based upon analysis of paracetamol absorption both in the fasted and 
different fed state conditions (FDA breakfast vs. nutritional drink vs. normal pig food). The 
study found that the shortest and most consistent gastric emptying rate was observed in the case 
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where the animals had access to normal pig food at the normal times of the day. It would appear 
therefore that further studies are required to elucidate whether the pig model is suitable for 
exploring fasted versus fed effects on oral bioavailability of drug products.  
 
Another factor for consideration in relation to transit time of dosage forms is the age of the pigs. 
Snoeck et al. [46] compared the investigated transit time of pellets in young suckling piglets to 
piglets in different post-weaning states. The gastric emptying rate in sucking pigs (3 week old 
4-6kg pigs) was faster compared to post-weaning pigs (4-7 week old 10-13kg pigs), with 75% 
of the pellets having emptied from the stomach within 1.5-3.5 hours. Three days postweaning, 
the gastric emptying time is markedly prolonged (75% of the pellets having emptied from the 
stomach within 25-34 hours). This delayed intestinal transit was most likely related to the 
change in diet (i.e. from sow’s milk to a dry diet) and social stress as a result of weaning. Three 
weeks post weaning, the gastric emptying rate appeared to return to norm with transit times 
similar to values reported in growing and adult pigs (75% pellets emptied within 7 hours). 
While the majority of pellets were emptied from the stomach within 24 hours in 3-week-weaned 
pigs, ~5% of pellets retained in the stomach 31 hours post dose. Furthermore, while transit of 
pellets in the small intestine and caecum were relatively rapid and complete, prolonged 
retention of pellets in the colon was also evident (85% pellets excretion within 50.5 hour). The 
authors therefore suggested that for certain types of pelletised dosage forms, extended retention 
in the porcine stomach and colon may need to be considered [46].  
 
The colonic transit time is highly variable in both pigs and humans.  In humans, estimates can 
range from 20 hours to > 2 days [47; 48]. Overall, the total gastrointestinal transit time in pigs, 
measured by roentgengenography, was reported to be between 2 and 33 days [6].  Even though 
this would appear longer than in humans, this may also reflect the slow and variable gastric 
emptying rate as discussed previously. 
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Given the significant variability observed with transit time as described previously, this may be 
due to different study protocols used as gastric emptying could depend on their normal feeding 
cycle, the fasting regime, the age and size of the pigs and amount and type of food. Therefore, 
a better standardisation of the study protocols would be favourable to obtain more comparable 
results of the different studies in order to improve the understanding of the gastric emptying in 
pigs. Further, the above results from various studies show that further studies with more 
subjects are needed to get a full understanding of the gastric emptying in pigs [21; 25; 6; 46]. 
 
In conclusion, the gastric emptying rate in pigs appears to be slower than in humans, whereas 
the small intestine transit time in pigs is similar to the ones reported in humans, for solids and 
liquids [41]. Given that a drug is absorbed in the small intestine and that the area for absorption 
in pigs is similar to the area in humans, pigs seem to be a suited species for investigation of 
drug absorption, with the precaution that the plasma sampling should be planned to take the 
potential slower gastric emptying rate into account. 
 
2.5 Intestinal metabolism and transporters. 
Another key consideration that can affect oral bioavailability is the prevalence of intestinally 
mediated first pass metabolism and/or efflux which can collectively limit drug access to the 
systemic circulation [49]. In humans it is known that CYP3A enzymes are responsible for 
metabolising approximately 48 % of the drugs currently on the market and account for more 
than 70 % of CYP enzymes present in the GI tract [50; 51]. Therefore, any differences in 
expression levels of intestinal enzymes and efflux transporters between humans and pigs may 
have a profound effect on the predictability of drug absorption in humans. 
 
Pig as a preclinical model of oral drug absorption 
Page 16 
 
While there is some data published in the literature regarding the expression profiles of 
important drug transporters (e.g. P-glycoprotein) and metabolising enzymes (e.g. CYP3A) in 
the GI tract of pre-clinical animals, the available data is limited. In the cases where these 
systems are involved in the metabolism or transport of certain drugs, a difference between 
humans and the animal models can be used to explain a lack of correlation between the species. 
For example, Cao et al. compared the transporter expression and metabolic enzyme expression 
in the duodenum between rat and human. The expression profile of 16 intestinal transporters 
displayed a moderate correlation (r2 = 0.56), whereas no correlation was found for the 
expression of metabolising enzymes between rat and human intestine [7]. This suggests a 
difference in intestinally metabolic capacity between the two different species and the 
challenges in predicting oral bioavailability in human. Relative to the more commonly utilised 
rat and dog models, studies reporting expression levels of intestinal transport/metabolising 
enzymes in pigs are sparse. With respect to the nutritional transporters Nøhr et al. [52] have 
demonstrated the presence of the proton coupled amino acid transporter (PAT1) in the small 
intestine and rectum in mini-pigs, a transporter also present in the human small intestine [53]. 
The level of PAT1 expression have, however, to the best of our knowledge not been quantified 
in mini-pigs. In general, the extend of homology between pigs and humans with respect to 
intestinal drug metabolising enzymes, efflux and influx transporters on both a qualitative and a 
quantitative level is unclear. Therefore, further mechanistic studies are required to identify 
inter-species commonalities and differences in transporter and/or metabolic profiles. 
 
2.6 Hepatic metabolising enzymes 
There are several families of CYP enzymes, each of which have subfamilies and unique 
isoforms. CYP isoforms are only found in one species, so a specific isoform of humans may 
have an orthologue in pigs, but an identical isoform is not found to date [54]. CYP3A in humans 
is the most important enzyme family metabolizing around 27% of drug compounds and 
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comprising 30% of the total CYP System [55]. The enzyme seems relatively well conserved in 
pigs and shows a very high similarity with the CYP3A4 in humans [56]. In particular, it seems 
that there are no major differences among CYP1A1, 1A2, 2B, 2E1 and 3A in pigs when 
compared to humans [57]. Hence, the pig may be a suitable pre-clinical model for drugs that are 
mainly metabolized by these CYP enzymes. In contrast the pig model is less suited for studies 
involving drugs that are metabolized by CYP2C and CYP2D. In humans the CYP2C and 
CYP2D metabolize about 22% and 12% of the drugs, respectively [55]. However porcine 
CYP2C and CYP2D display a distinctly different substrate specificity. A human CYP2C 
substrate, S-mephenytoin, was not metabolized by the pig, using liver microsomes. 
Furthermore, diclofenac and tolbutamid, two CYP2C substrates in humans [58], were 
metabolized to a lower extent in pigs compared to humans [57; 59]. The CYP2D activity generally 
seems higher in pigs than in humans [25; 29; 60; 61]. It is also worth considering that the various 
pig breeds may display different activity of hepatic enzymes. As recently reviewed, the 
Landrace pig demonstrated a presence and activity of CYP2D6 and CYP2C9 enzymes whereas 
Göttingen minipigs showed no activity of CYP2D6 and CYP2C9 enzymes [54].  
 
3 Oral bioavailability of drugs: comparing pigs versus humans 
To assess how well pig and human bioavailability correlate, a systematic review of the 
published literature was performed to identify previous studies where absolute bioavailability 
of drugs in pigs have been reported. Studies and compounds were only included where both 
oral and intravenous data was available, hence the absolute bioavailability could be calculated. 
Data from various pig breeds were included. The determination of absolute bioavailability was 
based on the traditional comparison between the area under the curve (AUC) after intravenous 
and oral administration:  
𝐹𝐹𝑎𝑎𝑎𝑎𝑎𝑎 =  �𝐴𝐴𝐴𝐴𝐴𝐴𝑜𝑜𝑜𝑜𝑎𝑎𝑜𝑜𝐴𝐴𝐴𝐴𝐴𝐴𝑖𝑖.𝑣𝑣. � ∗ � 𝐷𝐷𝐷𝐷𝐷𝐷𝑒𝑒𝑖𝑖.𝑣𝑣.𝐷𝐷𝐷𝐷𝐷𝐷𝑒𝑒𝑜𝑜𝑜𝑜𝑎𝑎𝑜𝑜�  
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In total, 20 compounds were identified to fulfil these criteria and the pharmacokinetic data for 
each compound in pigs and humans are summarized in Table 4. The degree of correlation of 
Fabs between the pig and human data are presented in Figure 4. A general positive trend towards 
predicting human bioavailability based on values in pigs was obtained, with a coefficient of 
determination r2 of 0.36. 
 
Looking at the individual drug level, the bioavailability in pigs is comparable to that in humans 
for the majority of drugs. However, there are specific drugs where the oral bioavailability data 
in pigs differed substantially from human data, which lowered the correlation observed overall 
between humans and pigs. On closer examination of this latter set, metoprolol and diclofenac 
appeared to display substantial differences in pigs relative to humans. This, most likely 
reflecting the different metabolic pathways for these drugs between the two species. Absolute 
oral bioavailability of metoprolol in pigs was reported to be as low as 3 %, whereas the buccal 
administration lead to a bioavailability of 58-107% [29]. These findings were in accordance with 
data published by Mogi et al. [61], who could not detect the plasma concentration of metoprolol 
after oral administration to pigs, as the plasma concentration where under the quantitation limit 
of the used bioanalysis. In humans the bioavailability of metoprolol is approximately 50%, a 
difference suggested to be driven by a difference in the metabolic pathway between the species. 
Metoprolol undergoes α-hydroxylation and O-demethylation through interactions with 
CYP2D6. As previously described, CYP2D has a higher activity in pigs than in humans, hence 
this difference most likely reflects extensive first pass metabolism of metoprolol in pigs. 
Interestingly, metoprolol bioavailability improved substantially to 58-107% following buccal 
administration to pigs, which supported the observations that first pass metabolism is the major 
limiting factor of metoprolol bioavailability in pigs [29]. Mogi and co-workers reported in vitro 
data of the oxidation process of metoprolol by liver enzymes from pigs and humans. The O-
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demethylation process of metoprolol was 10-fold faster by the pig microsomal system when 
compared to human liver microsomal system. This phenomenon is also reported for other 
compounds that are metabolised by CYP2D6, like dextromethorphan which shows a rapid and 
extensive metabolism in the pig and a O-demethylation process that is a 10-fold greater in pig 
liver microsomes compared to human liver microsomes [60]. It is important to mention that 
CYP2D6 metabolizes about 12% of all compounds, including β-blocker, antipsychotic as well 
antidepressant drugs [54]. Differences in the metabolic rate may also go in the other direction, 
i.e. humans metabolising faster than pigs. Diclofenac is a CYP2C substrate. Oberle and co-
workers [25] observed a higher bioavailability in pigs compared to human data., which was 
concluded to be a reflection of a different metabolism profile between the two species. 
Collectively, these examples underline the importance of looking at the hepatic metabolism 
when selecting the non-clinical species, but also provide an explanation why quantitative 
predictions and degree of correlations between pigs and humans is low (r2= 0.36). In general a 
head to head comparison of bioavailability across species may be difficult. 
 
Similar correlations comparing human bioavailability to other pre-clinical animal species have 
been described in the literature. Musther and co-workers [63] investigated the correlation of 
bioavailability data from dog, monkey, mouse, and rat with human bioavailability data. The 
correlation was conducted based upon a published data-set from Sietma et al. [64], where data 
from these animal models were reported. The data visualized the breadth of difference that exist 
between animal species and humans in terms of oral bioavailability. Musther et al. [63] 
highlighted the gaps in the correlation between the bioavailability in animals and humans and 
concluded that a quantitative prediction was not possible when comparing the bioavailability 
head to head. The extent of correlation was for monkey (r2= 0.69, 40 drugs), rat (r2= 0.29, 121 
drugs; r2= 0.21, 48 drugs), mouse (r2 of 0.25, 30 drugs) and dog (r2 = 0.38, 128 drugs; r2 = 0.15, 
49 drugs) [7; 9; 63; 65]. Based on the findings in the current study, the porcine model displayed a 
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higher overall correlation than both rodent models. The porcine model also compares 
favourably to the canine model, in terms of a similar coefficient previously reported for dogs. 
It should be noted that the number of drugs available with absolute bioavailability in pigs was 
lower (20) relative to the other species, reflecting key knowledge gaps in the literature and a 
need for further investigations to demonstrate more conclusive relationship. Moreover, sorting 
the data to exclude justifiable outliers, such as the species specific CYP2D metabolic difference 
could facilitate more informed conclusion. For example, excluding the values of Diclofenac 
and Metoprolol, which are two substances not suitable in the pig model, from the correlation 
illustrated in Figure 4, improved the correlation from r2= 0.36 to r2= 0.52. 
 
Additionally, to provide an insight on how the rate of drug absorption compares between pigs 
and humans, t max values were compared. Previously, t max has been used to evaluate gastric 
emptying, as a delayed emptying leads to a longer t max [43]. 
Within the group of drugs presented in Table 4, t max values were reported for only twelve of 
these drugs. T max values in pigs ranged from 0.6-5.0 (median 2.0) whereas in humans the 
range of t max values was 0.25-2.5 (median 1.9).  The larger range of t max values in pigs 
compared to humans most likely reflects a more variable gastric emptying in pigs, as discussed 
previously. Figure 5 illustrates the t max ratio between pigs and humans for each drug. As a 
general guide, t max in pigs was on average 2-fold higher than the corresponding value in 
humans. While there are individual drugs which do not follow this general guide, such as 
Ketoprofen where t max was 5-fold higher in pigs, and omeprazole was 4 fold higher in humans 
[73], these individual cases most likely reflects species specific differences in drug metabolism 
leading to extremes t max estimates.  It should also be noted that while t max is useful in the 
evaluation of gastric emptying, there are limitations to its reliability as an estimate of rate of 
drug absorption.  Differences in fasting/fed state conditions in the study design could affect 
gastric emptying and therefore need to be tightly controlled to ensure that appropriate 
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comparisons can be made. In addition, the value of tmax is highly influenced by the frequency 
of sampling within the study, and ideally most frequent sampling should be conducted near the 
expected peak plasma concentrations. The findings presented here would indicate that when 
designing plasma sampling studies involving pigs, frequent plasma sampling may be required 
for time periods up to 2 times the expected t max in humans. 
 
 
4 Pig versus dog in predicting human bioavailability: How do they 
compare? 
While the extents of correlation obtained for pigs vs. humans are comparable to values reported 
for dogs vs. humans, it should be acknowledged that there is a substantially more diverse drug 
data set available in the literature for dogs. In order to more reliably compare between species, 
the relationships of human bioavailability to both dogs and pigs were evaluated using only 
drugs which were common to both. In total a group of 15 drugs (from the 20 drugs of Table 4) 
were identified from the literature where absolute bioavailability was available in dogs, pigs 
and humans. Figure 6 presents the relationships obtained for these common set of drugs 
between pigs versus humans and dogs versus humans. For the set of 15 drugs identified, the 
coefficients of determinations obtained for pigs was r2 = 0.49, whereas for dogs r2 =0.35. Within 
both relationships, specific drugs could be identified where the oral bioavailability data in the 
animal correlated poorly to human data.  
 
In the case of absorption rate, it has previously been discussed that on average t max was longer 
in pigs than humans, most likely reflecting a slower gastric emptying in pigs. In the case of 
dogs, gastric emptying is considered to be more comparable to humans, however, few studies 
directly compare rates of absorption between the species.  Within the group of 15 drugs where 
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both canine, porcine and human data is available, there were only three drugs were a direct 
comparison of t max was possible. T max of moxifloxacin was 2.0 ± 1.9 hours, 4.0 ± 1.0 hours 
and 1.6 ± 2.9 hours in humans, pigs and dogs, respectively, confirming that while dogs and 
humans are similar, absorption in pigs appear to be marginally slower [66]. A similar trend is 
evident for ketoprofen with t max values of 0.8 hours, 3.9 ± 1.1 hours and 1.1 ± 0.3 hours in 
humans, pigs and dogs, respectively [72,73]. In the case of diclofenac differences are also 
prominent, a t max of 0.3 hours, 0.8 hours and 1.2 ± 0.6 hours was reported for humans, pigs 
and dogs, respectively [25,62]. 
 
In summary, while the number of drugs in the data-sets is limited, the findings demonstrate that 
pigs compare more favourably than dogs at predicting the extent of absolute bioavailability 
(Fabs) in humans, based on this limited set of comparable studies. The presented data therefore 
provide further evidence of the suitability of the pig in pre-clinical assessment of oral dosage 
forms. However, the rate of drug absorption in pigs is tending to be slower in pigs than humans, 
whereas in dogs, t max is more comparable to human estimates. In the case of drugs and/or 
formulations where a delayed rate of absorption might have a significant impact on in vivo 
performance (e.g. sustained release products or fast acting dosage forms), the canine model 
may offer advantages, notwithstanding the clear limitation where canine gastric pH is 
considerable higher than humans and pigs. 
 
 
5 The use of the pig model for assessing in vivo performance of oral dosage 
forms 
In drug formulation development it is crucial to assess the bioavailability of orally delivered 
drugs and in particular how this can be influenced by the use of different formulations in order 
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to support the formulation development work. Conductance of pre-clinical in vivo studies as 
well as in vitro and in silico approaches are often used in combination in order to understand 
the mechanisms that drive the absorption from the formulations tested before they are brought 
into human trials. Optimizing the steps from the in vitro work in the lab, linked to in vivo data 
from the animal studies can therefore help to expedite the process of development.  
 
The most common pre-clinical models to assess oral dosage forms, include, rats, dogs, pigs and 
less frequently non-human primates. Knowing which pre-clinical model to use in order to being 
able to compare different formulations as well as to predict oral bioavailability in humans is an 
important decision to generate data where conclusions can be drawn and the right formulation 
selected and taken into clinical trials in humans. However, there remains a lack of clarity in 
species selection for a specific formulation technology. This lack of clarity is particularly 
problematic for drug substances displaying low solubility and/or permeability (i.e. BCS Class 
II and IV), which generally requires bio-enabling formulations to improve oral bioavailability. 
While there are numerous oral drug delivery platform technologies to enhance oral 
bioavailability, it becomes increasingly clear that each formulation technology cannot be 
universally applied to all poorly water-soluble drugs and the selection of the correct formulation 
technology is often complicated (Figure 7.). As a result, a key question that needs to be 
addressed in selecting the most suitable pre-clinical model is: Which animal model will reliably 
predict the in vivo performance of a selected formulation technology, in particular bio-enabling 
formulation technology? 
 
Table 5, summarizes data from different formulation technologies with in vivo data from pigs, 
which has been reported in the literature. The objective is to summarise where the pig model 
has been utilised to demonstrate in vivo performance of specific formulation technology, and 
to act as a guide on which formulation technologies can be assessed using the pig model. Most 
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of the cases identified in Table 5 involve studies using formulation technologies that enhance 
oral bioavailability of poorly soluble drugs belonging to the BCS class II. Given the increasing 
number of new drugs in development with solubility limitations it is only a natural reflection 
of current focus in pharmaceutical research. The formulation technologies that have been 
assessed using pigs include micronized and nanosized formulations, as well as hot melt 
extrusion, lipid based and mesoporous silica formulation.  
 
The use of lipid based formulations as an approach to enhance oral bioavailability has increased 
in recent times. The drug absorption of lipid and surfactant based formulations can be affected 
by a variety of factors including characteristics on dilution in the intestinal fluids, solubilisation 
capacity of the drug during transit through the intestine, as well as the presence of food [91; 92]. 
It has been demonstrated that the lipid based formulations can not only enhance the solubility 
of the drug in the intestinal fluids, but also enhance the lymphatic uptake of the drug, which 
circumvents the first pass metabolism of the drug. This is predominantly present when the drug 
is given with long chain triglycerides and the drug has a log P >5 and a solubility in 
triglycerides > 50 mg/mL [93; 94], but exceptions also exists from this rule of thumb [95]. There 
are a variety of factors that must be considered in designing optimal lipid based formulations, 
for example the composition (commonly described by the LFCS classification system), the 
proportion and type of lipid surfactants and/or co-solvents. Upon digestion and the introduction 
of bile salts, the mixture of drug, lipids, surfactants and cosolvents is undergoing continual 
changes from an emulsion to lamellar and hexagonal phases and finally generating a pre-
absorptive mixed micellar state. Hence, in order to predict the behaviour of the drug in the GI 
tract it is crucial to have an advanced understanding of how the drug is solubilized and in which 
phases of the colloidal structure in the GI tract it can be found. It is a complex relation between 
lipid formulation and their pharmacokinetic properties. Several studies using lipid-based 
formulations have utilised a pig model to assess in vivo performance, see Table 5. Griffin and 
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co-workers showed for the lipophilic drug fenofibrate, that the pig model was suitable to assess 
the in-vivo performance of lipid-based formulations, showing predictably high oral absolute 
bioavailability in pigs (65-72%) [96]. T max values in pigs were 2.4-4.6 hours, which were 
similar to estimates in humans [97]. The in vivo results from the pig provided a better insight into 
the performance of different lipid based formulation classes, and enhanced the understanding 
on in vitro behaviour as well as the predictability of in vitro results. In addition, an in silico 
biopharmaceutical model was developed from this data to predict drug and lipid absorption 
during digestion of lipid based formulations, therein supporting the utility of pigs in mechanistic 
studies involving lipid based formulations [98]. In the case of fenofibrate, the pig model was also 
employed to compare novel mesoporous formulation to the commercially available nanosized 
Lipantil ® Supra. Interestingly the absolute bioavailability for nanosized Lipantil ® Supra 
observed in pigs was 71%, which was similar to the reported human data of 69% [69; 70]. Also 
the range of tmax in pigs matched the human data [70,71]. 
 
It should also be noted that a recent study by Thomas et al. exploring oral bioavailability of 
fenofibrate from a series of lipid based formulations in minipigs indicated that fenofibrate 
absorption in minipigs was considerably delayed [100]. T max of fenofibrate was 8 hours (0.5-
30 hours) from lipid based formulations [100]. Furthermore, t max of the micronized 
commercially available Lipanthyl 200 M capsules was 24 hours (8-72 hours) [100]. This may 
reflect differences in the study design (e.g. fed/fasting conditions, which affect gastric 
emptying), but also differences related to the breed of pigs used in the two studies, i.e. 
landrace and mini pigs, where the latter may display different pharmacokinetic properties for 
fenofibrate relative to humans and landrace pigs [101].   
 
The pig model has also been widely used to assess in vivo performance of a range of modified 
release formulations, see Table 5. For controlled release formulations, the mechanism of drug 
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release is dependent on the rate of degradation of the polymer, which controls the extent of drug 
diffusion through the polymer matrix. They are developed with the aim to reduce the frequency 
of dosing with a short terminal elimination half-life and to minimize the degree of fluctuation 
in the drug’s plasma concentration over the dosing intervals. It is likely that some of the 
difference in the GI physiology can influence the release and bioavailability of controlled-
release dosage forms. From a physiological perspective, pigs seem to be a suited surrogate for 
humans when evaluating controlled release formulations as each intestinal section, i.e. 
duodenum, jejunem, ilium and colon, is comparable. Furthermore, the bacterial flora of the 
colon is considered similar to man [17; 23]. For sustained release formulations a few studies have 
been reported in the literature where the pig was used as an animal model. For formulations 
with glipizide, the pig was reported to be a suitable model to predict modified release 
formulation performance. Kulkarni and co-workers [102] reported that the porcine absorption 
kinetics were consistent with the published clinical data, conversely the beagle dog was less 
consistent compared to humans. Kostewicz et al. investigated nifedipine sustained formulations 
in pigs, as described in Table 5, the obtained data was similar to data from a previously 
performed human study. Kostewicz and co-workers came to the conclusion that the obtained 
results suggested that the pig can be a useful model in differentiating the release profiles of 
nifedipine for the fed state in humans [104]. Another type of sustained release that has been tested 
in pigs are entero coated formulations. An important factor for these kind of systems is the pH 
in the stomach and the pH change upon entry into the small intestine. Pigs have a slower gastric 
emptying rate than humans, as discussed above, however a very similar pH in the stomach and 
the small intestine. The study conducted with entero coated formulations in pigs therefore 
resembled the release profile observed in humans well and pigs should in general be a suited 
model for evaluation of these systems.  
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Though very limited data are available comparing different formulation systems in pigs, they 
all indicate that pigs can be useful when evaluating both sustained release formulations as well 
as bio enabling formulations. This clearly demonstrates the relevance of the pig as a model to 
predict pharmacokinetics in human and the opportunity to use the pig for various formulation 
optimisation purposes.  
 
6 Role of in vitro and in silico models for predicting the suitability of pig 
models and the gaps in the current knowledge 
A key driver of the drug and formulation development processes is the ability to predict human 
pharmacokinetics (PK) as early as possible, in order to select candidates with the best 
developability, while rejecting those with a high probability of failure [108]. The intention of 
conducting in vivo pre-clinical studies in drug development is therefore to mitigate risk of 
developing medicines that are unsafe and/or ineffective in subsequent tests in humans, but 
equally important is to reduce the number of animals used for research purposes by appropriate 
application of in vivo studies. This is both an ethical and legislative obligation and the choice 
and number of animals has to be appropriately justified and must be in accordance with the  
3 R`s principle of replacement, reduction and refinement. In addition to the ‘reduction’ 
principle, ‘replacement’ options should always be considered, and this is where in vitro or in 
silico models can play a key role. Improvements in the correlation from in vitro data will help 
to reduce the number of animals needed. While the goal is to reduce the number of animals 
used, this reduction should not compromise the statistical outcome of the study, i.e. an 
underpowered study, as it makes the data unsuitable for decision making and therefore in 
principle unethical. Hence, the study should always include sufficient experimental units to 
obtain a precise and robust result that can lead to a correlation or prediction of the drug 
performance in humans.  
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Prediction of human pharmacokinetics generally relies on interpretation and extrapolation from 
in vitro and preclinical in vivo data [41]. There has been significant development in 
computational approaches to predict human pharmacokinetics, ranging from classical 
computational absorption simulation based on compartmental PK through to more complex 
physiologically based pharmacokinetic (PBPK) models, which can integrate data from both 
these sources to give an estimate of human PK [109]. A schematic presentation of the process is 
illustrated in Figure 8. The application of in silico modelling, with a specific focus on the use 
in pigs is discussed below. 
 
6.1 Reliable in vitro methods - biorelevant media 
The first step to characterize the dissolution and solubility behaviour of a drug, are reliable and 
appropriate in vitro models [110]. The selection of the media is a crucial step, biorelevant media 
simulating the human’s gastrointestinal conditions is a useful tool to get a first impression of 
the dissolution properties of a drug [111]. More important, with regard to the aim to reduce the 
number of animals, is to mimic the pre-clinical animal conditions. For common pre-clinical 
animal models, like dogs and rats, biorelevant dissolution media has been developed to simulate 
the gastrointestinal tract fluids of these species [112]. Properties such as pH, buffer capacity, 
osmolality, surface tension and hydrodynamic conditions were included to improve forecast 
and interpretation of pre-clinical results. For the pig the data is limited, there is a clear lack 
about the composition of porcine gastric and intestinal fluids, hence no biorelevant media is 
available for pigs why further work is needed to characterize intestinal porcine conditions. All 
in all, media specially designed for pre-clinical animal models will be essential to guide the 
selection of animal species suited for in vivo investigations of a drug candidate. 
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6.2 Computational models and in vitro- in vivo correlations (IVIVC) 
The simplest methods of predicting in vivo results is by means of an in vitro- in vivo correlation 
(IVIVC). Kesisoglou et al. demonstrated the use of a simple level C IVIVC in a retrospective 
analysis of the in vivo performance of extended release matrix and multi-particulate 
preparations of a BCS class III development candidate (MK-0941) with different targeted 
release rates (8hr, 12hr and 16 hr) in Yucatan minipigs. A good correlation between the in vitro 
release and bioavailability was reported [105]. Similarly, Keohane et al. demonstrated an in vitro- 
in vivo relationship (IVIVR) for coated microspheres containing Ciclosporin A. The resultant 
IVIVR demonstrated a strong linear correlation between in vitro release and in vivo absorption 
[82]. McCarthy et al., meanwhile, demonstrated the possibility of obtaining a level A IVIVC 
using such an approach, by optimising the biorelevance of the dissolution test for fenofibrate, 
as a model for poorly soluble compound. McCarthy and co-workers demonstrated that 
computational in silico methods could be used to deconvolute the oral absorption process from 
the pharmacokinetic profile, correlate this with in vitro release and model in vivo 
pharmacokinetics by re-convolution [70]. Govender et al. have recently proposed a similar 
approach to describe the absorption of amoxicillin from a delayed release, dual-biotic system 
[113]. 
 
Computational models based on the release and distribution kinetics of drug from formulations, 
modelled along with compartmental PK have also been implemented. Stillhart et al. developed 
a pharmacokinetic model in MatLab, based on simulating the intraluminal concentration and 
solubility of fenofibrate when delivered in three distinct lipid based formulations to fasted, 
juvenile Landrace pigs [98]. Using this biopharmaceutical model it was possible to accurately 
model plasma profiles, while also allowing a prediction of the intraluminal solubilisation, 
supersaturation and precipitation of the administered formulation. Using a model that 
considered the absorption of both the drug and lipid excipients after oral administration it was 
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possible to mechanistically investigate the in vivo performance in a manner not possible using 
simple in vitro digestion tests, which do not consider the impact of continuous absorption [98].  
 
6.3 Physiologically based pharmacokinetic models 
The distinguishing feature of PBPK models, relative to empirical computational models, is the 
application of prior physiological knowledge in the mechanistic mapping of model 
compartments and in the processes that determine absorption [104; 41]. This physiological 
knowledge, incorporating parameters such as gastrointestinal transit, pH and luminal volume, 
is combined with physiochemical measurements, e.g. dissociation constants and partition 
coefficients, and in vitro measurements, such as solubility and dissolution rates and enzymatic 
degradation kinetics, into the PBPK model in order to provide a simulated PK profile [109; 41; 
114]. PBPK models allow predictions of drug disposition based on a series of mass balance 
equations, which incorporate physiological, physiochemical and in vitro data within an in silico 
model [115]. Numerous commercial PBPK software systems are available, most notably Simcyp, 
GastroPlus™ and PK-Sim®, while there is also widespread use of user-built models, built using 
packages such as MATLAB®, Berkeley Madonna, MoBi®, STELLA® or acslX™ [114]. 
 
PBPK has a long history of use in veterinary pharmacology and toxicology. These studies have 
a particular focus on analysing xenobiotic disposition for the purposes of estimation of meat 
withdrawal periods based on residue depletion in edible tissue after either accidental exposure 
to a toxin or after off-label use of a veterinary preparation. Numerous reports of PBPK models 
being used to extrapolate disposition studies between species [115-119], estimate withdrawal 
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periods based on probabilistic methods [120; 121] and assessment of the potential for drug-drug 
interactions due to altered protein binding [122; 123] have been published. 
 
The growing use of the pig as a preclinical species of choice has led to significant developments 
in porcine PBPK models. Jones et al. developed a generic PBPK model for the prediction of 
clinical pharmacokinetics using preclinical data from various sources, including pigs, which 
proved superior to allometric scaling [108]. While significant differences remained in some cases, 
particularly when certain assumptions of the PBPK model were violated, the use of PBPK 
modelling provided insight into potential reasons for poor predictability, which allometric 
methods did not [110]. 
 
The most significant development in PBPK modelling in pigs was the minipig PBPK model 
developed using the advanced compartmental absorption (ACAT) model. By using a series of 
mass-balance equations that describe the specific physiology of the minipig, a porcine PBPK 
model was generated to simulate oral PK. The proposed model was initially validated with 
griseofulvin and moxifloxacin, with encouraging results [41]. However, the authors also 
identified areas where this model can further be refined, particularly in the areas of absorption 
related parameters and bile salt profiles within the minipig intestine. Further physiological 
characterisation along with pharmacokinetic analysis of well-chosen reference compounds, and 
adjustment of the model to reflect in vivo PK, was suggested to contribute to model refinement 
[41]. Subsequent work using paracetamol as a marker of GI motility and gastric emptying, was 
used to update this model. The updated model was subsequently validated on a number of PK 
studies in minipigs using omeprazole, caffeine, midazolam and warfarin. The prolonged gastric 
emptying in the re-parameterised PBPK model accurately predicted pharmacokinetics of this 
validation dataset in minipigs [44]. Studies such as those by Lignet et al. can further add to this 
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knowledge space, aiding the development and validation of this PBPK model by characterising 
the bioavailability of a set of reference compounds in the minipig model [86]. 
 
O’Shea et al. used the GastroPlus™ minipig ACAT PBPK model to simulate bioavailability of 
fenofibrate from a commercial micronized formulation and novel lipid based formulation in 
fasted landrace pigs [99]. Using this model, the authors successfully simulated fasted 
bioavailability for both formulations by incorporating the intravenous pharmacokinetic data, 
along with biorelevant in vitro solubility and dissolution measures into the mechanistic model. 
The model was subsequently used to extrapolate this data to the fed state, where the elimination 
of a food dependent increase in fenofibrate bioavailability utilising the novel formulation was 
predicted [99]. Kesisoglou et al. have also used the GastroPlus™ minipig model, in conjunction 
with modelling of dog and human data, in the formulation development of a modified release 
preparation of gaboxadol [124]. The authors successfully incorporated in vitro dissolution data 
and preclinical pharmacokinetic data within the PBPK models to guide formulation 
development. Subsequently, it was possible to use the minipig PBPK model to develop an 
IVIVC in order to project formulation performance [124]. Using regional permeability data 
measured in dogs and clinical pharmacokinetics from human studies, the minipig ACAT model 
was optimised using an immediate release dry filled capsule as a reference. Using this optimised 
model, the in vivo dissolution was deconvoluted from the simulated plasma profile for two 
modified release formulations. This in vivo dissolution profile was subsequently plotted against 
the in vitro release profile resulting in a linear IVIVC [124]. 
 
Lennernäs and co-workers have also developed porcine PBPK models, with a particular focus 
on simulating data from Landrace and Yorkshire pigs, which have multiple blood sampling 
sites. By measuring plasma concentrations in the hepatic, portal and femoral veins, along with 
biliary and urinary concentration, a detailed analysis of the ADME process was obtained [125]. 
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Sjögren et al. developed an 11 compartment PBPK pig model, to model drug concentrations in 
these sampling sites and estimate tissue distribution throughout a whole body PBPK model. 
This mechanistic PBPK model, in combination with appropriate in vitro assessment of enzyme 
kinetics and cellular disposition, allowed successful prediction of the influence of metabolism 
and carrier mediated processes on the hepatic disposition of repaglinide [125]. Similar models 
were used by Lennernäs and co-workers to investigate a potential drug-drug interaction 
between verapamil and fexofenadine [126] and to mechanistically investigate the effect of 
intracellular binding of doxorubicin on its PK in pigs [127]. 
 
The use of PBPK modelling during drug and formulation development is an emerging field for 
the prediction of preclinical and clinical PK using physiochemical and in vitro measurements. 
However, thus far the use of PBPK modelling has been largely confined to the retrospective, 
mechanistic analysis of preclinical data. While some work has focused on the extrapolation of 
these models to alternative formulations or dosing scenarios (e.g. in fed versus fasted state), 
and extrapolating between different preclinical species, there is still a lack of prospective 
models used in formulation design. There remains a need for systematic studies utilising PBPK 
models as part of a ‘learn and confirm’ paradigm before the full benefit of this approach is 
realised. 
 
7 Conclusion 
This review has investigated the potential advantage and suitability of the pig as a pre-clinical 
model within pharmaceutical sciences. From an anatomical and physiological perspective, the 
pig model is widely recognized and displays high similarities to the GI conditions of humans. 
There remain striking gaps in our knowledge about the pig model and its utility to predict 
human bioavailability of oral dosage forms, as discussed above. Analysis of the available 
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literature for absolute bioavailability studies conducted in pigs, dogs and humans demonstrated 
that the pigs compared favourably to dogs in terms of predicting human bioavailability.  
As a result of the limited data available in the literature, it is currently not possible to make 
quantitatively predictions of human bioavailability. 
 
While this review has provided specific examples of limitation of pigs, such as drugs 
metabolised extensively by the CYP2D system, there is overall a need to harness knowledge 
from a wider range of drug molecules (both successes and failures) to develop better guides as 
to which drug formulation that are best suited for testing in pigs. There is also an opportunity 
to improve the link between in vitro screening and in vivo testing in preclinical animals. This 
could be the development of species specific biorelevant screening tool, which is currently not 
available for pigs.  
 
Clearly, there is no “one size fits all” choice in the context of preclinical animal modelling, 
hence there is no “ideal” species that represent all aspects of human GI conditions [9]. With the 
data presented in the present work it is reasonable to state that the pig model is similar to most 
physiological conditions in man and hence a model suitable for considering when conducting 
in vivo studies. 
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Table 1 Comparison of the pH in the GI tract of pigs versus human 
Segment Human   Minipig 1) Landrace pig 
Fasted pH  
[23; 24]  
Fed pH  
[24; 4] 
Fasted pH 
[25] 
Fed pH 
[25] 
Fasted pH 
[21; 4] 2) 
Fed pH 
[26]  
Stomach 1.0-3.5 3.0-6.0 0.3-1.7 3.6  1.2-4.0 4.4  
Duodenum 6.0-7.0  5.0-5.5 
7-8 n.a. 
6.7 6.1-6.5  
Jejunum 6.0-7.7 5.0-6.5 6.8 6.3-6.6 
Ileum 6.5-8.0 6.5-8.0 6.9 6.5-6.7 
Colon 5.5-8.0  6.0-7.5 n.a. n.a. 6.1-6.6 6.5-6.6  
n.a.: not available; 1) Yucatan minipig 2) in house data (12 pigs) 
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Table 2 Total small intestine surface areas of pig and human, adapted from DeSesso et. al, [27] 
 Pig Human 
Body weight [kg] 47  70 
Smooth luminal surface area [m2] 1.4  0.42  
Fold-increase factors Plicae 1 3  
Villi 6 10  
Micro-villi 20-25 20  
Combined multiplication factor 120 600 
Estimated total surface area [m2] 168-210 252 
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Table 3 Major bile components in pigs and humans, based on published data [36]: *primary, 
**secondary bile acids 
 Pig Human 
Conjugation Taurine, Glycine Taurine, Glycine 
Major bile acids Cholate (C)*, 
Hyocholate (HC)*, 
Hyodeoxycholate 
(HDC)** 
Cholate (C)*, 
Chenodeoxycholate 
(CDC)*,  
Deoxycholate (DC)**  
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Table 4 Comparison of oral in vivo data from pigs and humans from various pharmacokinetic studies.  
Compound 
Name 
PK parameters pigs PK parameters human Ref. 
Pig F 
abs [%] 
t1/2 [h] Vd 
[L/kg] 
Cl 
[L/(h*kg)] 
T max 
[h] 
Human F 
abs [%] 
t1/2 [h] Vd 
[L/kg] 
Cl 
[L/(h*kg)] 
T max 
[h]  
Moxifloxacin1) 54 ± 103 11.0 ± 1.1 3.8 ± 1.2 0.7 ± 1.39 4.0 ± 1.01 82 ± 19.7 12.0 2.2 0.1 2.0 ± 1.90 [66] 
Trimethoprim2) 90 ± 11 n.r. 1.8 0.6 2.1± 1.2 98 ± 22.4 10.9 1.6 0.1 1.8 ± 0.7 [67; 68] 
Fenofibrate2) 71 ± 26 n.r. n.r. n.r. 5.0 ± 2.4 69 ± 10.8 20.0 ± 7.7 n.r. n.r. 2.33 ± 0.73** [69-71] 
Ketoprofen2) 86 ± 20 0.8 ± 0.2 0.4 ± 0.2 0.7 ± 0.2 3.85 ± 1.13 85 ± 20.1 1.3 ± 0.3 n.r. n.r. 0.75 [72; 73] 
Metoprolol1) 3 ± 1 n.r. 7.7 ± 0.7 4.4 ± 0.6 0.88 ± 0.38 50 ± 7.0 3.5 ± 0.2 4.0± 0.3 n.r. n.r. [74; 29] 
Vigabatrin1) 75 ± 4 n.r. n.r. 0.2 ± 0.1 0.5 85 ± 5* n.r. n.r. n.r. n.r. [75; 52] 
Diazepam1) 31 ± 6 n.r. 0.05 0.1. 4.8 ± 0.8 94 n.r. n.r. n.r. 2.5 [76; 77] 
Amoxicillin2) 33 ± 14 9.9 ± 4.3 0.6 ± 0.2 0.5 ± 0.1 1.9 ± 0.9 65 ± 11.4 1.2 ± 0.1 0.5± 0.1 0.3 2.06 ± 0.43 [78; 79] 
Cyclosporine2) 58 ± 33 n.r. n.r. n.r. 2.17 ± 0.15 60 n.r. n.r. n.r. n.r. [80-82] 
Paracetamol1) 83 ± 29 3.8 ± 0.3 0.7 ± 0.1 5.3 ± 1.1 1.38 89 ± 4 n.r. n.r. n.r. 0.73 ± 0.42 [83; 44] 
Omeprazole3) 11 ± 7 0.6 ± 0.1 n.r. n.r. 0.6 ± 0.3 41 ± 1.5* n.r. n.r. n.r. 2.5 [84; 61] 
Midazolam1) 12 1.0 ± 0.4 1.3 22.3 ± 8.6 3.0 ± 3.4 44 ± 17 n.r. n.r. n.r. 1.5 ± 0.33 [85; 64; 86] 
Theophylline1) 108 11.9 ± 4.5 0.9 ± 0.1 1.1 ± 0.4 2.6 ± 1.2 103 ± 10.2 0.3 ± 0.2 n.r.. n.r. n.r. [87; 86] 
Cimetidine1) 33 0.8 ± 0.1 1.5 ± 0.2 37.4 ± 8.2 1.7 ±1.0 78 1.7± 0.4 n.r. n.r. 0.83 [88; 86] 
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n.r.= not reported. Including absolute bioavailability (Fabs), half-life (t1/2), volume of distribution (Vd), clearance (Cl) and time of peak plasma 
concentration (t max) for 20 compounds. Different pig breeds were included:  1)Göttingen Minipig. 2) LR pigs. 3)Microminipig. 4)Yucatan Minipig 
*Range. **different PK study [71] 
 
  
Hydrochlorothiazide1) 62 5.2 ± 1.2 3.2 ± 0.8 11.8 ± 1.6 2.3 ± 1.5 72 ± 17 n.r. n.r. n.r. n.r. [64; 86] 
Atenolol1) 34 4.4 ± 1.5 1.5 ± 0.1 7.9 ± 2.9 1.6 ± 0.5 58 ± 16 6.7 ± 2.6 n.r. 9.3 ± 1.2 2.5 ± 1.1 [89; 86] 
Phenazone1) 36 ± 10 9.3 ± 5.8 0.8 ± 03 1.5 ± 0.9 2.4 ± 1.3 91 ± 10* n.r. n.r. n.r. n.r. [64; 86] 
Warfarin3) 84 ± 38 17 ± 12 n.r. n.r. 11 ± 9 93 ± 8 n.r. n.r. n.r. n.r. [64; 61] 
Caffeine3) 79 ± 28 11 ± 4 n.r. n.r. 3.3 ± 2.2 80 ± 16 n.r. n.r. n.r. n.r. [90; 61] 
Diclofenac4) 107 ± 5 n.r. n.r. n.r. 0.75 42 ± 27 n.r. n.r. n.r. 0.25 [62]] 
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Table 5 Summary of in vivo studies in pigs involving assessment of in vivo performance of various formulation technologies(MP=minipig; LR= 
landrace pig) 
Formulation 
technology 
Drug 
Pig 
species 
Dosage 
[mg/ 
kg] 
Formulation type in vivo performance 
Formulation 
components 
Ref. 
Bio-enabling 
formulation 
 
Fenofibrate 
 
LR 
 
3.72 
Mesoporous 
Silica 
Formulation 
SBA-15 
slower rate of drug absorption due 
to a slower release (compare to 
Lipantil Supra) 
Fenofibrtae loading onto 
SBA-15 
251.3 mg drug/g silica 
[69; 70] 
3.72 
Nanosized 
Formulation 
Reference 
formulation 
Fabs 71%  not significant higher 
than micronized commercial 
products, it is  similar to reported 
human oral bioavailability of 69% 
Lipantil ® Supra 145 mg film 
coated tablets 
Bio-enabling 
formulation 
 
Fenofibrate 
 
LR 
 
5.48 
Lipid based 
formulations 
LFCS Type 
IIIA 
Bioavailability is similar to the 
LFCS Type IIIB/IV (nearly 70% 
Fabs)  
40% Miglyol, 20% 
Cremophor RH, 40%, Tween 
85 
[96] 
5.84 
Lipid based 
formulations 
LFCS Type 
IIIB/IV 
No major differences within tmax 
and cmax values due to the other 
LBF of Fenofibrate 
33% Cremophor RH, 67% 
Tween 85 
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Formulation 
technology 
Drug 
Pig 
species 
Dosage 
[mg/ 
kg] 
Formulation type in vivo performance 
Formulation 
components 
Ref. 
4.32 
Micronized 
Formulation 
Reference 
Formulation 
The absolute bioavailability was 
66% a little bit lower than the 
LBF above. 
Lipantil® Micro 67 mg hard 
Capsules (Abbott) 
[99] 
Bio-enabling 
formulation 
 
Fenofibrate 
 
MP 
 
16.06 
Micronized 
Formulation 
Reference 
Formulation 
No apparent difference in the 
overall extent of bioavailability 
between Lipanthyl and the 
SNEDDs below, t max 
performance: 1:3 (Lipanthyl : 
SNEDDs below) 
Lipanthyl 200 M capsules 
containing micronized 
Fenoﬁbrate (Abbot AG) 
[100] 
Bio-enabling 
formulation 
 
Fenofibrate 
 
MP 
 
16.06 
Lipid based 
formulations 
SNEDDS 
Very similar in vivo performance 
of the various SNEDDs 
formulation 
  24 % soybean, 32.2 % 
Maisine 35-1, 30% Kolliphor 
RH 40, 13.8% Ethanol 
(75 % drug load) 
[100] 
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Formulation 
technology 
Drug 
Pig 
species 
Dosage 
[mg/ 
kg] 
Formulation type in vivo performance 
Formulation 
components 
Ref. 
16.06 
Lipid based 
formulations 
Supersaturated 
SNEDDS 
All SNEDDs showed an increase 
rate of drug absorption (higher 
cmax) compared to Lipanthyl 
same LBF 
(150 % drug load) 
16.06 
Lipid based 
formulations 
SNEDDS-
suspension 
In vivo performance of the 
SNEDDS was signiﬁcantly 
enhanced compared to 
commercial Lipanthyl 
same LBF 
(100+ 50% drug load) 
Modified 
Release 
Formulations 
 
Glipizide LR 0.42 
Sustained 
Release 
Commercial 
product 
F 92% in pig compare to only 
21% bioavailability in beagle 
dogs. Hence the pig is a better 
model to predict MR formulation 
performance (human F is 95%) 
Glucotrol XL® [102] 
Theophylline MP 9.09 
Sustained 
Release 
Capsule (300 
mg of EC-
coated beads) 
Frel was low, close to 50% 
compared to an oral solution 
34% Theophylline, 20% 
Sucrose, 34% Nonpareil-103, 
[103] 
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Formulation 
technology 
Drug 
Pig 
species 
Dosage 
[mg/ 
kg] 
Formulation type in vivo performance 
Formulation 
components 
Ref. 
9% Sucrose, 3% Ethyl-
cellulose  
Nifedipine LR 1.58 
Sustained 
Release 
Pellets in 
gelatine 
capsule 
Difference in the absorption 
characteristics of the two 
formulations (experimental 
formulation and Procardia XL) 
n.a. [104] 
Nifedipine LR 1.58 
Sustained 
Release 
oral osmatic 
pump 
The mean Cmax is considerably 
higher for the experimental 
formulation when compared 
against Procardia XL 
Procardia XL tablet (Pfizer) [105] 
Modified 
Release 
Formulations 
 
MK-0941 
(BCS class III) 
Yucatan 
MP 
0.08 
Sustained 
Release 
Matrix tablet 
The pharmacokinetic performance 
of the matrix table and 
multiparticulate formulation was 
comparable 
Hydroxypropyl 
methylcellulose based matrix 
tablets 
[105] 
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Formulation 
technology 
Drug 
Pig 
species 
Dosage 
[mg/ 
kg] 
Formulation type in vivo performance 
Formulation 
components 
Ref. 
MK-0941 
(BCS class III) 
Yucatan 
MP 
0.08 
Sustained 
Release 
Multiparticulat
e formulation 
The in vivo performance in pigs 
appeared to reasonably reflect the 
clinical performance 
Multiparticulate formulation 
consisted of a drug-containing 
core with a EC-based coating, 
filled in a capsules 
Penicillamine LR 10.95 Enteric coated Coated tablet 
The shape of the plasma 
concentration curve was similar to 
that in human. The Frel  66.5% 
compared with the uncoated table  
5 layers of cellulose acetate 
phthalate formulation 
[106] 
Octreotide LR 0.64 Enteric coated 
Coated 
Capsule 
Different composition were 
tested, combination with Chitosan 
as an extra absorption enhancer 
demonstrate the best 
bioavailability (16.1%)  
1) core: ocreotide 2) conveyor 
system: super-porous hydrogel 
(SPH) 3) placed in enteric 
coated capsule (Eudragit 
S100) 
[107] 
 
  
Pig as a preclinical model of oral drug absorption 
Page 59 
 
 
Figure 1 Relative gastrointestinal (GI) length [%] of sections of the GI tract from: published 
pig (crossbreed of large white and landrace)*[26] and human data [4; 27]; in comparison to LR 
(unpublished data) **. 
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Figure 2 Conversion of Cholesterol into primary and secondary bile acids, adapted scheme from Ref. [32]; . 
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Figure 3 Rank order of prevalence of bile salts (A) Pigs, GHC= Glycohyocholate; GCDC= 
Glycochenodeoxycholate; GHDC= Glycohyodeoxycholate; THC= Taurohyocholate; TCDC= 
Taurochenodeoxycholate; based on the reported data from Scanff et al. [40], (B) human bile 
salts, GC= Glycocholate; GCDC= Glycochenodeoxycholate; GDC= Glyco-deoxycholate; 
TC= Tauro-cholate; TCDC= Tauro-chendeoxycholate. [38] 
 
 
 
Figure 4 Direct correlation between the oral bioavailability in human and pig of the 
compounds presented in Table 4. 
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Figure 5 T max ratios of pig/human values for 12 drugs of Table 4. 
 
 
Figure 6 Direct correlation of oral bioavailability: human versus dog and human versus pig, 
for 15 compounds presented in Table 4. 
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Figure 7 Role of the pig model in formulation development 
 
 
Figure 8 A schematic presentation of the compound selection and formulation optimisation 
process and the placement of in silico model in the processes  
